{
    "organizations": [],
    "uuid": "11c4371e7ae44c086485135430edfd38813f2a35",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/clearside-study/clearside-biomedicals-eye-treatment-succeeds-late-stage-study-idUSL4N1QN4GH",
    "ord_in_thread": 0,
    "title": "Clearside Biomedical's eye treatment succeeds late-stage study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - Clearside Biomedical Inc said on Monday its treatment for fluid build-up in the eye had met the main goal of a late-stage study.\nShares of the Alpharetta, Georgia-based drug developer jumped 52.2 percent at $11.90 in premarket trading.\nThe drug was being tested in patients with macular edema associated with non-infectious uveitis.\nReporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur\n ",
    "published": "2018-03-05T20:31:00.000+02:00",
    "crawled": "2018-03-06T22:24:36.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "clearside",
        "biomedical",
        "inc",
        "said",
        "monday",
        "treatment",
        "fluid",
        "eye",
        "met",
        "main",
        "goal",
        "study",
        "share",
        "alpharetta",
        "drug",
        "developer",
        "jumped",
        "percent",
        "premarket",
        "trading",
        "drug",
        "tested",
        "patient",
        "macular",
        "edema",
        "associated",
        "uveitis",
        "reporting",
        "manas",
        "mishra",
        "bengaluru",
        "editing",
        "arun",
        "koyyur"
    ]
}